| Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment (NCT00678119) | Argos Therapeutics | 2008-01-01 |
| Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma (NCT00556049) | Massachusetts General Hospital | 2007-12-01 |
| Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone (NCT00609934) | University Health Network, Toronto | 2007-12-01 |
| Tumor Registry of Advanced Renal Cell Carcinoma (NCT00610012) | iOMEDICO AG | 2007-12-01 |
| Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma (NCT01441661) | Cancer Foundation, China | 2007-11-01 |
| Treatment of Advanced Renal Cell Carcinoma With Quinacrine (NCT00574483) | Cleveland BioLabs | 2007-11-01 |
| A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma (NCT00563147) | AVEO Pharmaceuticals, Inc. | 2007-11-01 |
| Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma (NCT00561912) | M.D. Anderson Cancer Center | 2007-10-01 |
| A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma (NCT00480935) | University Health Network, Toronto | 2007-10-01 |
| Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib (NCT00474786) | Pfizer | 2007-09-01 |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) (NCT00491738) | Genentech, Inc. | 2007-08-01 |
| Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients (NCT00617253) | Novo Nordisk A/S | 2007-07-12 |
| Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma (NCT00496587) | M.D. Anderson Cancer Center | 2007-07-01 |
| A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma (NCT00485563) | Endocyte | 2007-06-01 |
| RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma (NCT00601120) | Beth Israel Deaconess Medical Center | 2007-06-01 |
| Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) (NCT00478114) | Mahidol University | 2007-05-01 |
| Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal (NCT00480389) | University Health Network, Toronto | 2007-05-01 |
| IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease (NCT00523159) | Immatics Biotechnologies GmbH | 2007-05-01 |
| A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. (NCT00378482) | AstraZeneca | 2007-03-05 |
| T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY) (NCT00717743) | National University Hospital, Singapore | 2007-03-01 |
| A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer (NCT00448721) | AEterna Zentaris | 2007-03-01 |
| A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma (NCT00417677) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-03-01 |
| SUTENT® In The First Line Treatment Of Renal Cell Carcinoma (NCT00460798) | Pfizer | 2007-02-01 |
| Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma (NCT00423332) | AstraZeneca | 2007-01-01 |
| ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma (NCT00420888) | Active Biotech AB | 2007-01-01 |
| Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) (NCT00609401) | Italian Trial in Medical Oncology | 2006-11-01 |
| A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma (NCT00422344) | Memorial Sloan Kettering Cancer Center | 2006-10-01 |
| Zoledronate With Atorvastatin in Renal Cell Carcinoma (NCT00490698) | M.D. Anderson Cancer Center | 2006-10-01 |
| Sorafenib and RAD001 Renal Cell Carcinoma (NCT00384969) | University of California, San Francisco | 2006-10-01 |
| [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours (NCT00323076) | AHS Cancer Control Alberta | 2006-09-12 |
| Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) (NCT00923169) | National Cancer Institute (NCI) | 2006-07-09 |
| Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma (NCT00353301) | University of Colorado, Denver | 2006-07-01 |
| Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow (NCT00330564) | M.D. Anderson Cancer Center | 2006-05-01 |
| Study of Kidney Tumors in Younger Patients (NCT00898365) | Children's Oncology Group | 2006-02-27 |
| Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer (NCT00272649) | Argos Therapeutics | 2006-01-01 |
| Pemetrexed Plus Gemcitabine in Renal Cell Cancer (NCT00491075) | M.D. Anderson Cancer Center | 2005-12-01 |
| Study of XL999 in Patients With Metastatic Renal Cell Carcinoma (NCT00277316) | Symphony Evolution, Inc. | 2005-12-01 |
| Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 (NCT00199875) | Ludwig Institute for Cancer Research | 2005-07-06 |
| Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer (NCT00126178) | Agenus Inc. | 2005-05-01 |
| Use of Tracking Devices to Locate Abnormalities During Invasive Procedures (NCT00102544) | National Institutes of Health Clinical Center (CC) | 2005-02-23 |
| Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma (NCT00113217) | M.D. Anderson Cancer Center | 2005-02-01 |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) (NCT00100685) | Abbott | 2005-01-01 |
| Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma (NCT00258687) | Dana-Farber Cancer Institute | 2005-01-01 |
| Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer (NCT01176552) | Kidney Cancer Research Bureau | 2004-05-01 |
| A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma (NCT00081614) | Genentech, Inc. | 2004-03-01 |
| A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies (NCT02829775) | Hoffmann-La Roche | 2004-01-01 |
| RNA-Loaded Dendritic Cell Cancer Vaccine (NCT00087984) | Argos Therapeutics | 2004-01-01 |
| ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer (NCT00056537) | Active Biotech AB | 2003-04-01 |
| A Comparative Study Between AirSeal, an Integrated Insufflation System, and Conventional Insufflation (NCT02075658) | University of California, Irvine | 2003-01-01 |
| A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma (NCT00625755) | Beth Israel Deaconess Medical Center | 2002-12-01 |
| Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma (NCT00082459) | Agenus Inc. | 2002-07-01 |
| BMS 247550 to Treat Kidney Cancer (NCT00030992) | National Cancer Institute (NCI) | 2002-02-01 |
| Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States (NCT00340457) | National Cancer Institute (NCI) | 2001-11-16 |
| Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia (NCT00513175) | University of California, San Francisco | 2001-10-01 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| Study of CP-461 in Patients With Advanced Renal Cell Cancer (NCT00036036) | Astellas Pharma Inc | 2001-07-01 |
| Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance (NCT00026663) | National Cancer Institute (NCI) | 2000-08-09 |
| Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer (NCT00033904) | Agenus Inc. | 2000-06-01 |
| Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma (NCT00001703) | National Cancer Institute (NCI) | 1998-08-01 |
| Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders (NCT00001238) | National Cancer Institute (NCI) | 1990-12-05 |
| Tazemetostat Expanded Access Program for Adults With Solid Tumors (NCT03874455) | Epizyme, Inc. | |
| Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA (NCT00006431) | National Center for Research Resources (NCRR) | |